Abbott Laboratories Hits New 52-Week Low at USD 93.94

Abbott Laboratories has reached a new 52-week low, trading at USD 93.94 as of April 16, 2026. This significant decline highlights the stock's performance over the past year, which has seen a decrease of 11.18%. In contrast, the S&P 500 has experienced a robust gain of 33.47% during the same period, underscoring the challenges faced by Abbott in the current market environment. The company operates within the Pharmaceuticals & Biotechnology sector and boasts a market capitalization of USD 214,677 million. Abbott's price-to-earnings (P/E) ratio stands at 32.00, reflecting its valuation relative to earnings. Despite the recent price drop, Abbott maintains a low debt-to-equity ratio of 0.10, indicating a strong ability to manage its debt obligations. In terms of operational performance, Abbott has reported positive results for the last three consecutive quarters, with an operating cash flow peaking at USD 9,037 million. The company's return on capital employed (ROCE) is currently at 13.01%, suggesting a solid return on investments. As Abbott navigates these market dynamics, its financial metrics will be closely monitored by stakeholders.